Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2014

Open Access 01-12-2014 | Research article

The glomerular parietal epithelial cell’s responses are influenced by SM22 alpha levels

Authors: Shokichi Naito, Jeffrey W Pippin, Stuart J Shankland

Published in: BMC Nephrology | Issue 1/2014

Login to get access

Abstract

Background

Studies have shown in several diseases initially affecting podocytes, that the neighboring glomerular parietal epithelial cells (PECs) are secondarily involved. The PEC response might be reparative under certain circumstances, yet injurious under others. The factors governing these are not well understood. We have shown that SM22α, an actin-binding protein considered a marker of smooth muscle differentiation, is upregulated in podocytes and PECs in several models of podocyte disease. However, the impact of SM22α levels on PECs is not known.

Methods

Experimental glomerular disease, characterized by primary podocyte injury, was induced in aged-matched SM22α +/+ and SM22α -/- mice by intraperitoneal injection of sheep anti-rabbit glomeruli antibody. Immunostaining methods were employed on days 7 and 14 of disease.

Results

The number of PEC transition cells, defined as cells co-expressing a PEC protein (PAX2) and podocyte protein (Synaptopodin) was higher in diseased SM22α -/- mice compared with SM22α +/+ mice. WT1 staining along Bowman’s capsule is higher in diseased SM22α -/- mice. This was accompanied by increased PEC proliferation (measured by ki-67 staining), and an increase in immunostaining for the progenitor marker NCAM, in a subpopulation of PECs in diseased SM22α -/- mice. In addition, immunostaining for vimentin and alpha smooth muscle actin, markers of epithelial-to-mesenchymal transition (EMT), was lower in diseased SM22α -/- mice compared to diseased SM22α+/+ mice.

Conclusion

SM22α levels may impact how PECs respond following a primary podocyte injury in experimental glomerular disease. Absent/lower levels favor an increase in PEC transition cells and PECs expressing a progenitor marker, and a lower EMT rate compared to SM22α +/+ mice, where SM22 levels are markedly increased in PECs.
Appendix
Available only for authorised users
Literature
1.
Marshall CB, Shankland SJ: Cell cycle regulatory proteins in podocyte health and disease. Nephron Exp Nephrol. 2007, 106 (2): e51-e59. 10.1159/000101793.CrossRefPubMed
2.
Shankland SJ: The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006, 69 (12): 2131-2147. 10.1038/sj.ki.5000410.CrossRefPubMed
3.
Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997, 99 (2): 342-348. 10.1172/JCI119163.CrossRefPubMedPubMedCentral
4.
Lerco MM, Macedo CS, Silva RJ, Pinheiro Dde O, Spadella CT: The number of podocyte and slit diaphragm is decreased in experimental diabetic nephropathy. Acta Cir Bras. 2006, 21 (2): 87-91.CrossRefPubMed
5.
Wiggins RC: The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int. 2007, 71 (12): 1205-1214. 10.1038/sj.ki.5002222.CrossRefPubMed
6.
Kim YH, Goyal M, Kurnit D, Wharram B, Wiggins J, Holzman L, Kershaw D, Wiggins R: Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int. 2001, 60 (3): 957-968. 10.1046/j.1523-1755.2001.060003957.x.CrossRefPubMed
7.
Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Holzman LB, Wiggins RC: Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol. 2005, 16 (10): 2941-2952. 10.1681/ASN.2005010055.CrossRefPubMed
8.
Appel D, Kershaw DB, Smeets B, Yuan G, Fuss A, Frye B, Elger M, Kriz W, Floege J, Moeller MJ: Recruitment of podocytes from glomerular parietal epithelial cells. J Am Soc Nephrol. 2009, 20 (2): 333-343. 10.1681/ASN.2008070795.CrossRefPubMedPubMedCentral
9.
Ronconi E, Sagrinati C, Angelotti ML, Lazzeri E, Mazzinghi B, Ballerini L, Parente E, Becherucci F, Gacci M, Carini M, Maggi E, Serio M, Vannelli GB, Lasagni L, Romagnani S, Romagnani P: Regeneration of glomerular podocytes by human renal progenitors. J Am Soc Nephrol. 2009, 20 (2): 322-332. 10.1681/ASN.2008070709.CrossRefPubMedPubMedCentral
10.
Sagrinati C, Netti GS, Mazzinghi B, Lazzeri E, Liotta F, Frosali F, Ronconi E, Meini C, Gacci M, Squecco R, Carini M, Gesualdo L, Francini F, Maggi E, Annunziato F, Lasagni L, Serio M, Romagnani S, Romagnani P: Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol. 2006, 17 (9): 2443-2456. 10.1681/ASN.2006010089.CrossRefPubMed
11.
Ohse T, Vaughan MR, Kopp JB, Krofft RD, Marshall CB, Chang AM, Hudkins KL, Alpers CE, Pippin JW, Shankland SJ: De novo expression of podocyte proteins in parietal epithelial cells during experimental glomerular disease. Am J Physiol Renal Physiol. 2010, 298 (3): F702-F711. 10.1152/ajprenal.00428.2009.CrossRefPubMed
12.
Zhang J, Hansen KM, Pippin JW, Chang AM, Taniguchi Y, Krofft RD, Pickering SG, Liu ZH, Abrass CK, Shankland SJ: De novo expression of podocyte proteins in parietal epithelial cells in experimental aging nephropathy. Am J Physiol Renal Physiol. 2012, 302 (5): F571-F580. 10.1152/ajprenal.00516.2011.CrossRefPubMed
13.
Zhang J, Pippin JW, Krofft RD, Naito S, Liu ZH, Shankland SJ: Podocyte repopulation by renal progenitor cells following glucocorticoids treatment in experimental FSGS. Am J Physiol Renal Physiol. 2013, 304 (11): F1375-F1389. 10.1152/ajprenal.00020.2013.CrossRefPubMedPubMedCentral
14.
Zhang J, Pippin JW, Vaughan MR, Krofft RD, Taniguchi Y, Romagnani P, Nelson PJ, Liu ZH, Shankland SJ: Retinoids Augment the Expression of Podocyte Proteins by Glomerular Parietal Epithelial Cells in Experimental Glomerular Disease. Nephron Exp Nephrol. 2012, 121 (1): e23-e37.CrossRefPubMedPubMedCentral
15.
Romagnani P, Remuzzi G: Renal progenitors in non-diabetic and diabetic nephropathies. Trends Endocrinol Metab. 2013, 24 (1): 13-20. 10.1016/j.tem.2012.09.002.CrossRefPubMed
16.
Berger K, Schulte K, Boor P, Kuppe C, van Kuppevelt TH, Floege J, Smeets B, Moeller MJ: The Regenerative Potential of Parietal Epithelial Cells in Adult Mice. J Am Soc Nephrol. 2014, 25 (4): 693-705. 10.1681/ASN.2013050481.CrossRefPubMedPubMedCentral
17.
Wanner N, Hartleben B, Herbach N, Goedel M, Stickel N, Zeiser R, Walz G, Moeller MJ, Grahammer F, Huber TB: Unraveling the Role of Podocyte Turnover in Glomerular Aging and Injury. J Am Soc Nephrol. 2014, 25 (4): 707-716. 10.1681/ASN.2013050452. [Epub ahead of print]CrossRefPubMedPubMedCentral
18.
Schulte K, Berger K, Boor P, Jirak P, Gelman IH, Arkill KP, Neal CR, Kriz W, Floege J, Smeets B, Moeller MJ: Origin of parietal podocytes in atubular glomeruli mapped by lineage tracing. J Am Soc Nephrol. 2014, 25 (1): 129-141. 10.1681/ASN.2013040376.CrossRefPubMed
19.
Sakamoto K, Ueno T, Kobayashi N, Hara S, Takashima Y, Pastan I, Matsusaka T, Nagata M: The direction and role of phenotypic transition between podocytes and parietal epithelial cells in focal segmental glomerulosclerosis. Am J Physiol Renal Physiol. 2014, 306 (1): F98-F104. 10.1152/ajprenal.00228.2013.CrossRefPubMed
20.
Shankland SJ, Anders HJ, Romagnani P: Glomerular parietal epithelial cells in kidney physiology, pathology, and repair. Curr Opin Nephrol Hypertens. 2013, 22 (3): 302-309. 10.1097/MNH.0b013e32835fefd4.CrossRefPubMed
21.
Ohse T, Pippin JW, Chang AM, Krofft RD, Miner JH, Vaughan MR, Shankland SJ: The enigmatic parietal epithelial cell is finally getting noticed: a review. Kidney Int. 2009, 76 (12): 1225-1238. 10.1038/ki.2009.386.CrossRefPubMedPubMedCentral
22.
Bariety J, Hill GS, Mandet C, Irinopoulou T, Jacquot C, Meyrier A, Bruneval P: Glomerular epithelial-mesenchymal transdifferentiation in pauci-immune crescentic glomerulonephritis. Nephrol Dial Transplant. 2003, 18 (9): 1777-1784. 10.1093/ndt/gfg231.CrossRefPubMed
23.
Ng YY, Fan JM, Mu W, Nikolic-Paterson DJ, Yang WC, Huang TP, Atkins RC, Lan HY: Glomerular epithelial-myofibroblast transdifferentiation in the evolution of glomerular crescent formation. Nephrol Dial Transplant. 1999, 14 (12): 2860-2872. 10.1093/ndt/14.12.2860.CrossRefPubMed
24.
Fujigaki Y, Sun DF, Fujimoto T, Suzuki T, Goto T, Yonemura K, Morioka T, Yaoita E, Hishida A: Mechanisms and kinetics of Bowman's epithelial-myofibroblast transdifferentiation in the formation of glomerular crescents. Nephron. 2002, 92 (1): 203-212. 10.1159/000064469.CrossRefPubMed
25.
Yadav A, Vallabu S, Kumar D, Ding G, Charney DN, Chander PN, Singhal PC: HIVAN phenotype: consequence of epithelial mesenchymal transdifferentiation. Am J Physiol Renal Physiol. 2010, 298 (3): F734-F744. 10.1152/ajprenal.00415.2009.CrossRefPubMed
26.
Swetha G, Chandra V, Phadnis S, Bhonde R: Glomerular parietal epithelial cells of adult murine kidney undergo EMT to generate cells with traits of renal progenitors. J Cell Mol Med. 2011, 15 (2): 396-413. 10.1111/j.1582-4934.2009.00937.x.CrossRefPubMed
27.
Sakamaki Y, Sakatsume M, Wang X, Inomata S, Yamamoto T, Gejyo F, Narita I, Inomata S, Yamamoto T, Gejyo F, Narita I: Injured kidney cells express SM22alpha (transgelin): Unique features distinct from alpha-smooth muscle actin (alphaSMA). Nephrology (Carlton). 2011, 16 (2): 211-218. 10.1111/j.1440-1797.2010.01322.x.CrossRef
28.
Nishida W, Kitami Y, Hiwada K: cDNA cloning and mRNA expression of calponin and SM22 in rat aorta smooth muscle cells. Gene. 1993, 130 (2): 297-302. 10.1016/0378-1119(93)90435-6.CrossRefPubMed
29.
Assinder SJ, Stanton JA, Prasad PD: Transgelin: an actin-binding protein and tumour suppressor. Int J Biochem Cell Biol. 2009, 41 (3): 482-486. 10.1016/j.biocel.2008.02.011.CrossRefPubMed
30.
Ogawa A, Sakatsume M, Wang X, Sakamaki Y, Tsubata Y, Alchi B, Kuroda T, Kawachi H, Narita I, Shimizu F, Gejyo F: SM22alpha: the novel phenotype marker of injured glomerular epithelial cells in anti-glomerular basement membrane nephritis. Nephron Exp Nephrol. 2007, 106 (3): e77-e87. 10.1159/000103020.CrossRefPubMed
31.
Wang X, Sakatsume M, Sakamaki Y, Inomata S, Yamamoto T, Narita I: Quantitative histological analysis of SM22alpha (transgelin) in an adriamycin-induced focal segmental glomerulosclerosis model. Nephron Exp Nephrol. 2012, 120 (1): e1-e11. 10.1159/000329664.CrossRefPubMed
32.
Marshall CB, Krofft RD, Blonski MJ, Kowalewska J, Logar CM, Pippin JW, Kim F, Feil R, Alpers CE, Shankland SJ: Role of smooth muscle protein SM22alpha in glomerular epithelial cell injury. Am J Physiol Renal Physiol. 2011, 300 (4): F1026-F1042. 10.1152/ajprenal.00187.2010.CrossRefPubMedPubMedCentral
33.
Zhang JC, Kim S, Helmke BP, Yu WW, Du KL, Lu MM, Strobeck M, Yu Q, Parmacek MS: Analysis of SM22alpha-deficient mice reveals unanticipated insights into smooth muscle cell differentiation and function. Mol Cell Biol. 2001, 21 (4): 1336-1344. 10.1128/MCB.2001.21.4.1336-1344.2001.CrossRefPubMedPubMedCentral
34.
Hauser PV, Perco P, Muhlberger I, Mühlberger I, Pippin J, Blonski M, Mayer B, Alpers CE, Oberbauer R, Shankland SJ: Microarray and bioinformatics analysis of gene expression in experimental membranous nephropathy. Nephron Exp Nephrol. 2009, 112 (2): e43-e58. 10.1159/000213505.CrossRefPubMed
35.
Miao J, Fan Q, Cui Q, Zhang H, Chen L, Wang S, Guan N, Guan Y, Ding J: Newly identified cytoskeletal components are associated with dynamic changes of podocyte foot processes. Nephrol Dial Transplant. 2009, 24 (11): 3297-3305. 10.1093/ndt/gfp338.CrossRefPubMed
36.
Inomata S, Sakatsume M, Sakamaki Y, Wang X, Goto S, Yamamoto T, Gejyo F, Narita I: Expression of SM22alpha (transgelin) in glomerular and interstitial renal injury. Nephron Exp Nephrol. 2011, 117 (4): e104-e113. 10.1159/000320175.CrossRefPubMed
37.
Daniel C, Lüdke A, Wagner A, Todorov VT, Hohenstein B, Hugo C: Transgelin is a marker of repopulating mesangial cells after injury and promotes their proliferation and migration. Lab Invest. 2012, 92 (6): 812-826. 10.1038/labinvest.2012.63.CrossRefPubMed
38.
Karagianni F, Prakoura N, Kaltsa G, Politis P, Arvaniti E, Kaltezioti V, Psarras S, Pagakis S, Katsimboulas M, Abed A, Chatziantoniou C, Charonis A: Transgelin Up-Regulation in Obstructive Nephropathy. PLoS One. 2013, 8 (6): e66887-10.1371/journal.pone.0066887.CrossRefPubMedPubMedCentral
39.
Ichimura K, Kawashima Y, Nakamura T, Powell R, Hidoh Y, Terai S, Sakaida I, Kodera Y, Tsuji T, Ma JX, Sakai T, Matsumoto H, Obara T: Medaka fish, Oryzias latipes, as a model for human obesity-related glomerulopathy. Biochem Biophys Res Commun. 2013, 431 (4): 712-717. 10.1016/j.bbrc.2013.01.053.CrossRefPubMedPubMedCentral
40.
Smeets B, Moeller MJ: Parietal epithelial cells and podocytes in glomerular diseases. Semin Nephrol. 2012, 32 (4): 357-367. 10.1016/j.semnephrol.2012.06.007.CrossRefPubMed
41.
Romagnani P: Parietal epithelial cells: their role in health and disease. Contrib Nephrol. 2011, 169: 23-36.CrossRefPubMed
42.
Pippin JW, Brinkkoetter PT, Cormack-Aboud FC, Durvasula RV, Hauser PV, Kowalewska J, Krofft RD, Logar CM, Marshall CB, Ohse T, Shankland SJ: Inducible rodent models of acquired podocyte diseases. Am J Physiol Renal Physiol. 2009, 296 (2): F213-F229.CrossRefPubMed
43.
Pippin JW, Sparks MA, Glenn ST, Buitrago S, Coffman TM, Duffield JS, Gross KW, Shankland SJ: Cells of renin lineage are progenitors of podocytes and parietal epithelial cells in experimental glomerular disease. Am J Pathol. 2013, 183 (2): 542-557. 10.1016/j.ajpath.2013.04.024.CrossRefPubMedPubMedCentral
44.
Benigni A, Morigi M, Rizzo P, Gagliardini E, Rota C, Abbate M, Ghezzi S, Remuzzi A, Remuzzi G: Inhibiting angiotensin-converting enzyme promotes renal repair by limiting progenitor cell proliferation and restoring the glomerular architecture. Am J Pathol. 2011, 179 (2): 628-638. 10.1016/j.ajpath.2011.04.003.CrossRefPubMedPubMedCentral
45.
Mundlos S, Pelletier J, Darveau A, Bachmann M, Winterpacht A, Zabel B: Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues. Development. 1993, 119 (4): 1329-1341.PubMed
46.
Bariety J, Mandet C, Hill GS, Bruneval P: Parietal podocytes in normal human glomeruli. J Am Soc Nephrol. 2006, 17 (10): 2770-2780. 10.1681/ASN.2006040325.CrossRefPubMed
47.
Urruticoechea A, Smith IE, Dowsett M: Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005, 23 (28): 7212-7220. 10.1200/JCO.2005.07.501.CrossRefPubMed
48.
Zoja C, Garcia PB, Rota C, Conti S, Gagliardini E, Corna D, Zanchi C, Bigini P, Benigni A, Remuzzi G, Morigi M: Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. Am J Physiol Renal Physiol. 2012, 303 (9): F1370-F1381. 10.1152/ajprenal.00057.2012.CrossRefPubMed
49.
Abbate M, Brown D, Bonventre JV: Expression of NCAM recapitulates tubulogenic development in kidneys recovering from acute ischemia. Am J Physiol. 1999, 277 (3 Pt 2): F454-F463.PubMed
50.
51.
Pode-Shakked N, Metsuyanim S, Rom-Gross E, Mor Y, Fridman E, Goldstein I, Amariglio N, Rechavi G, Keshet G, Dekel B: Developmental tumourigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population. J Cell Mol Med. 2009, 13 (8B): 1792-1808. 10.1111/j.1582-4934.2008.00607.x.CrossRefPubMed
52.
Dong LH, Wen JK, Liu G, McNutt MA, Miao SB, Gao R, Zheng B, Zhang H, Han M: Blockade of the Ras-extracellular signal-regulated kinase 1/2 pathway is involved in smooth muscle 22 alpha-mediated suppression of vascular smooth muscle cell proliferation and neointima hyperplasia. Arterioscler Thromb Vasc Biol. 2010, 30 (4): 683-691. 10.1161/ATVBAHA.109.200501.CrossRefPubMed
53.
Yang Z, Chang YJ, Miyamoto H, Ni J, Niu Y, Chen Z, Chen YL, Yao JL, di Sant'Agnese PA, Chang C: Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth. Mol Endocrinol. 2007, 21 (2): 343-358. 10.1210/me.2006-0104.CrossRefPubMed
54.
Yeo M, Park HJ, Kim DK, Kim YB, Cheong JY, Lee KJ, Cho SW: Loss of SM22 is a characteristic signature of colon carcinogenesis and its restoration suppresses colon tumorigenicity in vivo and in vitro. Cancer. 2010, 116 (11): 2581-2589.PubMed
55.
Gunnersen JM, Spirkoska V, Smith PE, Danks RA, Tan SS: Growth and migration markers of rat C6 glioma cells identified by serial analysis of gene expression. Glia. 2000, 32 (2): 146-154. 10.1002/1098-1136(200011)32:2<146::AID-GLIA40>3.0.CO;2-3.CrossRefPubMed
56.
Pang J, Liu WP, Liu XP, Li LY, Fang YQ, Sun QP, Liu SJ, Li MT, Su ZL, Gao X: Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis. J Proteome Res. 2010, 9 (1): 216-226. 10.1021/pr900953s.CrossRefPubMed
57.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008, 133 (4): 704-715. 10.1016/j.cell.2008.03.027.CrossRefPubMedPubMedCentral
58.
Shimizu M, Kondo S, Urushihara M, Takamatsu M, Kanemoto K, Nagata M, Kagami S: Role of integrin-linked kinase in epithelial-mesenchymal transition in crescent formation of experimental glomerulonephritis. Nephrol Dial Transplant. 2006, 21 (9): 2380-2390. 10.1093/ndt/gfl243.CrossRefPubMed
Metadata
Title
The glomerular parietal epithelial cell’s responses are influenced by SM22 alpha levels
Authors
Shokichi Naito
Jeffrey W Pippin
Stuart J Shankland
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2014
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-15-174

Other articles of this Issue 1/2014

BMC Nephrology 1/2014 Go to the issue

Case report

Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma

Research article

Incidental findings on cardiac computed tomography in incident hemodialysis patients: the predictors of arrhythmic and cardiovascular events in end-stage renal disease (PACE) study

Research article

Nephrologists’ perspectives on dialysis treatment: results of an international survey

Research article

Non-inferiority of creatinine excretion rate to urinary L-FABP and NGAL as predictors of early renal allograft function

Research article

Prevalence of microalbuminuria and diagnostic value of dipstick proteinuria in outpatients from HIV clinics in Bukavu, the Democratic Republic of Congo

Research article

Cardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits